GSK completes $10.6bn acquisition of Nuvalent
- Location
- London / Cambridge (Massachusetts) · 🇬🇧 United Kingdom / USA
- Sector
- Pharma
- Organisations
- GSK plc ↔ Nuvalent Inc.
- Transaction
- Acquisition (completion)
- Volume
- $10.6bn (approx. £8.0bn)
- Status
- completed
UK pharma group GSK completed its acquisition of US oncology specialist Nuvalent on 15 July (equity value approx. $10.6bn, approx. $9.4bn net of cash). GSK gains three lung-cancer assets, two of them under FDA review (PDUFA dates September/November 2026). Source is the SEC 6-K filing; second source: Investing.com.
Source: sec.gov ↗ · Archived copy ↗
Evidence: one source · second source missing (two-source rule) · How well sourced is Eurotrack?
More from: 🇬🇧 United Kingdom · 🇺🇸 USA